AI spending is booming, but how do we know the new technology solutions driven by these investments are fulfilling their promise and driving a positive impact on healthcare? New AI-enabled solutions must have a direct impact on patients’ lives and the long-term cost of care. Trusted partners and proven technology are a key ingredient to meeting this goal.
To truly impact healthcare, AI solutions must deliver a combination of clinical, and economic improvements. These solutions must provide answers, not more analysis. They must be seamlessly integrated into the existing workflow. It is key that this new technology moves us beyond productivity to provide deep patient diagnostic insights. This requires deep clinical validation, healthcare standards-based execution such as cyber-secure with leading 3rd party validated certification and regulatory approvals. In addition, these solutions must be scalable and supportable, ready to deploy globally via trusted OEM CT and PACS channels.
MaxQ AI’s ACCIPIO ICH and Stroke Suite is already commercially deployed through major CT, AI ecosystem, and PACS channel partners – including GE Healthcare (CT and PACS), IBM Watson Healthcare, Philips (CT and PACS), FujiFilm, TeraRecon, Nuance, Blackford Analysis, and Samsung Neurologica. Our partners distribute our comprehensive AI suite as part of their integrated solutions through their worldwide channels seamlessly to the physician, with “no clicks,” fully secure and supported.
To learn more about MaxQ AI and the industry-leading, trusted OEM CT, PACS software, Radiology Reporting, and AI Platform companies deploying our solution, or to request a demo, visit us at maxq.ai. Follow us via LinkedIn.
*References upon request
*MaxQ AI Device Regulatory Status